References
- 1. Smolen JS, Aletaha D, Barton A et al. Rheumatoid arthritis. Nat Rev Dis Primers 2018; 4: 18001. doi:10.1038/nrdp.2018.1
- 2. Zhang Y, Lu N, Peloquin C, Dubreuil M, Neogi T, Avi a-Zubieta JA, et al. Improved survival in rheumatoid arthritis: a general population-based cohort study. Rheum Dis 2017; 76: 408-13.
- 3. Markusse IM, Akdemir G, Dirven L, Goekoop-Ruiterman YP, van Groenendael JH, Han KH, et al. Long-term outcomes of patients with recent-onset rheumatoid arthritis after 10 years of tight controlled treatment: a randomized trial. Ann Intern Med 2016; 164: 523-31.
- 4. Lacaille D, Avina-Zubieta JA, Sayre EC, Abrahamowicz M. Improvement in 5-year mortality in incident rheumatoid arthritis compared with the general population-closing the mortality gap. Ann Rheum Dis 2017; 76: 1057-63.
- 5. Carpenter L, Norton S, Nikiphorou E, Jayakumar K, McWilliams DF, Rennie KL, et al. Early rheumatoid arthritis study and the early rheumatoid arthritis Reductions in radiographic progression in early rheumatoid arthritis over twenty-five years: changing contribution from rheumatoid factor in two multicenter UK inception cohorts. Arthritis Care Res (Hoboken) 2017; 69: 1809-17.
- 6. Zhao J, Li Z. The challenges of early diagnosis and therapeutic prediction in rheumatoid arthtirtis. Int J Rheum Dis 2018; 21(12): 2059-62.
- 7. Oderda GM, Lawless GD, Wright GC et al. The potential impact of monitoring disease activity biomarkers on rheumatoid arthritis outcomes and costs. Pers Med 2018; 15(4): 291–301. doi:10.2217/pme-2018-0001
- 8. Qin B, Yang M, Fu H, et al. Body mass index and the risk of rheumatoid arthritis: a systematic review and dose-response meta-analysis. Arthritis Res Ther 2015; 17(1): 1–12. doi:10.1186/s13075-014-0514-045
- 9. Feng J, Chen Q, Yu F, et al. Body mass index and risk of rheumatoid arthritis a meta-analysis of observational studies. Med (Baltimore) 2016; 95(8): e2859
- 10. DOI: 10.1097/MD.0000000000002859.
- 11. Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. Life Sci 2011; 121(6): 2111–17
- 12. Ellerby N, Mattey DL, Packham J, Dawes P, Hider SL. Obesity and comorbidity are independently associated with a failure to achieve remission in patients with established rheumatoid arthritis. Ann Rheum Dis 2014; 73(11): 1–3. doi:10.1136/annrheumdis-2014-20625449
- 13. Sandberg MEC, Bengtsson C, Källberg H, et al. Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis. Ann Rheum Dis 2014; 73(11): 2029–33. doi:10.1136/annrheumdis-2013-20509450
- 14. Ajeganova S, Andersson ML, Hafström I. Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: a long-term followup from disease onset. Arthritis Care Res 2013; 65(1): 78–87. doi:10.1002/acr.2171051
- 15. Chaparro‐Sanabria JA, Bautista‐Molano W, Bello‐Gualtero JM et al. Association of adipokines with rheumatic disease activity indexes and periodontal disease in patients with early rheumatoid arthritis and their first‐degree relatives. Int J Rheum Dis 2019; doi:10.1111/1756-185x.13724
- 16. Laurberg TB, Fraystyk J, Ellingsen T, Hansen IT, Jorgensen A, Tarp U et al. Plasma adiponectin in patients with active, early, and chronic rheumatoid arthritis who are steroid‐ and disease‐modifying antirheumatic drugnaive compared with patients with osteoarthritis and controls. J Rheumatol 2009; 36(9): 1885-91.
- 17. Manrique-Arija S, Urena I, Valdivielso P, Rioja J, Jimenez-Nunez FG, Irigoyen MV et al. Insulin resistance and levels of adipokines in patients with untreated early rheumatoid arthritis. Clin Rheumatol 2016; 35(1): 43-53.
- 18. El‐Hini SH, Mohamed FI, Hassan AA, Ali F, Mahmoud A, Ibraheem HM. Visfatin and adiponectin as novel markers for evaluation of metabolic disturbance in recently diagnosed rheumatoid arthritis patients. Rheumatol Int 2013; 33 (9): 2283‐89.
- 19. Barbosa, Vitalina de Souza, Rêgo, Jozelia, & Silva, Nílzio Antônio da. Possible role of adipokines in systemic lupus erythematosus and rheumatoid arthritis. Revista Brasileira de Reumatologia 2012; 52(2): 278-287. doi:10.1590/S0482-50042012000200011
- 20. Lee SW, Park MC, Park YB, Lee SK. Measurement of the serum leptin level could assist disease activity monitoring in rheumatoid arthritis. Rheumatol Int 2007; 27(6): 537–40.
- 21. Seven A, Güzel S, Aslan M, Hamuryudan V. Serum and synovial fluid leptin levels and markers of inflammation in rheumatoid arthritis. Rheumatol Int 2009; 29(7): 743–7.
- 22. Giles JT, Allison M, Bingham CO 3rd, Scott WM Jr, Bathon JM. Adiponectin is a mediator of the inverse association of adiposity with radiographic damage in rheumatoid arthritis. Arthritis Rheum 2009; 61(9): 1248–56.
- 23. Rho YH, Solus J, Sokka T, Oeser A, Chung CP, Gebretsadik T et al. Adipocytokines are associated with radiographic joint damage in rheumatoid arthritis. Arthritis Rheum 2009; 60(7): 1906–14.
- 24. Azamar-Llamas D, Hernández-Molina G, Ramos-Ávalos B, Furuzawa-Carballeda J. Adipokine Contribution to the Pathogenesis of Osteoarthritis. Mediators of Inflammation 2017; 1–26. doi:10.1155/2017/5468023
- 25. Yan M, Zhang J, Yang H, Sun Y. The role of leptin in osteoarthritis. Medicine 2018; 97(14). e0257. doi:10.1097/md.0000000000010257
- 26. Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 1995; 83(7): 1263–71.
- 27. Tartaglia LA. The leptin receptor. J Biol Chem 1997; 272(10): 6093–6.
- 28. Westhoff G, Rau R, Zink A. Radiographic joint damage in early rheumatoid arthritis is highly dependent on body mass index. Arthritis Rheum 2007; 56(11): 3575–82.
- 29. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995; 269(5223): 540–3.
- 30. Gainsford T, Willson TA, Metcalf D, Handman E, McFarlane C, Ng A et al. Leptin can induce proliferation, differentiation, and functional activation of hemopoietic cells. Proc Natl Acad Sci USA 1996; 93(25): 14564–8.
- 31. Del Prete A, Salvi V, Sozzani S. Adipokines as potential biomarkers in rheumatoid arthritis. Mediat Inflamm 2014; 1–11. doi:10.1155/2014/425068.
- 32. Sanchez-Margalet V, Martin-Romero C, Santos-Alvarez J, Goberna R, Najib S, Gonzalez-Yanes C. Role of leptin as an immunomodulator of blood mononuclear cells: mechanisms of action. Clin Exp Immunol 2003; 133(1): 11–9.
- 33. Gómez R, Conde J, Scotece M, Gómez-Reino JJ, Lago F, Gualillo O. What’s new in our understanding of the role of adipokines in rheumatic diseases? Nat Rev Rheumatol 2011; 7(9): 528–36. doi:10.1038/nrrheum.2011.107
- 34. Lord GM, Matarese G, Howard JK, Bloom SR, Lechler RI. Leptin inhibits the anti-CD3-driven proliferation of peripheral blood T cells but enhances the production of proinflammatory cytokines. J Leukoc Biol 2002; 72(2): 330–8.
- 35. Targońska-Stępniak, B., Dryglewska, M., & Majdan, M. (2009). Adiponectin and leptin serum concentrations in patients with rheumatoid arthritis. Rheumatology International, 30(6), 731–737.doi:10.1007/s00296-009-1053-x
- 36. Anders H, Rihl M, Heufelder A, Loch O, Schattenkirchner M. Leptin serum levels are not correlated with disease activity in patients with rheumatoid arthritis. Metabolism 1999; 48:745–8.
- 37. Nishiya K, Nishiyama M, Chang A, Shinto A, Hashimoto K. Serum leptin levels in patients with rheumatoid arthritis are correlated with body mass index. Rinsho Byori 2002; 50(5): 524–7.
- 38. Popa C, Netea MG, Radstake TR, van Riel PL, Barrera P, van der Meer JWM. Markers of inflammation are negatively correlated with serum leptin in rheumatoid arthritis. Ann Rheum Dis 2005; 64: 1195–8.
- 39. Hizmetli S, Kisa M, Gokalp N, Bakici MZ. Are plasma and synovial fluid leptin levels correlated with disease activity in rheumatoid arthritis? Rheumatol Int 2007; 27: 335–8.
- 40. Tokarczyk-Knapik A, Nowicki M, Wyromlak J. The relation between plasma leptin concentration and body fat mass in patients with rheumatoid arthritis. Pol Arch Med Wewn 2002; 108: 761–7.
- 41. Bokarewa M, Bokarew D, Hultgren O, Tarkowski A. Leptin consumption in the inflamed joints of patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62: 952–6.
- 42. Salazar-Paramo M, Gonzalez-Ortiz M, Gonzalez-Lopez L, Sanchez-Ortis A, Valera-Gonzalez IC, Martinez-Abundis E et al. Serum leptin levels in patients with rheumatoid arthritis. J Clin Rheumatol 2001; 7: 57–9.
- 43. Yoshino T, Kusunoki N, Tanaka N, Kaneko K, Kusunoki Y, Endo H et al. Elevated serum levels of resistin, leptin, and adiponectin are associated with C-reactive protein and also other clinical conditions in rheumatoid arthritis. Intern Med 2011; 50(4): 269–75.
- 44. Bustos Rivera-Bahena C, Xibillé-Friedmann DX, González-Christen J, Carrillo-Vázquez SM, Montiel-Hernández JL. Peripheral blood leptin and resistin levels as clinical activity biomarkers in Mexican rheumatoid arthritis patients. Reumatol Clin 2016; 12(6): 323–6.
- 45. Tian G, Liang JN, Wang ZY, Zhou D. Emerging role of leptin in rheumatoid arthritis. Clin Exp Immunol 2014; 177(3): 557–70.
- 46. Lee YH, Bae SC. Circulating leptin level in rheumatoid arthritis and its correlation with disease activity: a metaanalysis. Z Rheumatol 2016; 75(10): 1021–27.
- 47. Olama SM, Senna MK, Elarman M. Synovial/serum leptin ratio in rheumatoid arthritis: the association with activity and erosion. Rheumatol Int 2012; 32: 683−90. doi.org/10.1007/s00296-010-1698-5
- 48. Xibille-Friedmann DX, Bustos-Bahena C, Hernandez-Gongora S, Burgos-Vargas R, Montiel JL. Two-year follow-up of plasma leptin and other cytokines in patients with rheumatoid arthritis. Ann Rheum Dis 2010; 69(5): 930-1.
- 49. Allam A, Radwan A. The relationship of serum leptin levels with disease activity in Egyptian patients with rheumatoid arthritis. Egypt Rheumatol 2012; 34(4): 185–90.
- 50. Abdalla M, Effat D, Sheta M, Hamed WE. Serum leptin levels in rheumatoid arthritis and relationship with disease activity. Egypt Rheumatol 2014; 36(1): 1–5.
- 51. Oner SY, Volkan O, Oner C, Mengi A, Direskeneli H, Tasan DA. Serum leptin levels do not correlate with disease activity in rheumatoid arthritis. Acta Reumatol Port 2015; 40(1): 50–4.
- 52. Mirfeizi Z, Noubakht Z, Rezaie AE, Jokar MH, Sarabi ZS. Plasma levels of leptin and visfatin in rheumatoid arthritis patients; is there any relationship with joint damage? Iran J Basic Med Sci 2014; 17(9): 662–6.
- 53. Carrión M, Frommer KW, Pérez-García S, Müller-Ladner U, Gomariz RP, Neumann E. The adipokine network in rheumatic joint diseases. Int J Mol Sci 2019; 20(17): 4091. doi:10.3390/ijms20174091
- 54. Toussirot E. Mini-Review: The contribution of adipokines to joint inflammation in inflammatory rheumatic diseases. Front Endocrinol 2020 (decembar); 11:606560. doi: 10.3389/fendo.2020.606560
- 55. Neumann E, Frommer KW, Vasile M, Muller-Ladner U. Adipocytokines as driving forces in rheumatoid arthritis and related inflammatory diseases? Arthritis Rheum 2011; 63: 1159–69.
- 56. Reverchon M, Ramé C, Bertoldo M, Dupont J. Adipokines and the female reproductive tract. Int J Endocrinol 2014; doi.org/10.1155/2014/232454
- 57. Yamauchi T, Kamon J, Waki H et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7(8); 941–6.
- 58. Chen X, Lu J, Bao J, Guo J, Shi J, Wang Y. Adiponectin: a biomarker for rheumatoid arthritis? Cytokine Growth Factor Rev 2013; 24(1): 83–9.
- 59. Szumilas K, Szumilas P, Słuczanowska-Głąbowska S, Zgutka K, Pawlik A. Role of adiponectin in the pathogenesis of rheumatoid arthritis. Int J Mol Sci 2020; 21(21): 8265. doi:10.3390/ijms21218265.
- 60. Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta 2007; 380: 24–30.
- 61. Lago R, Gomez R, Otero M, Lago F, Gallego R, Dieguez C et al. A new player in cartilage homeostasis: adiponectin induces nitric oxide synthase type II and pro-inflammatory cytokines in chondrocytes. Osteoarthr Cartilage 2008; 16: 1101–9.
- 62. Takemura Y, Walsh K, Quchi N. Adiponectin and cardiovascular inflammatory responses. Curr Atheroscl Rep 2007; 9(3), 238–43.
- 63. Otero M, Lago R, Gomez R, Lago F, Dieguez C, Gómez-Reino JJ et al. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65:1198–201.
- 64. Ozgen M, Koca SS, Dagli N, Balin M, Ustundag B, Isik A. Serum adiponectin and vaspin levels in rheumatoid arthritis. Arch Med Res 2010; 41: 457–63.
- 65. Giles JT, van der Heijde DM, Bathon JM. Association of circulating adiponectin levels with progression of radiographic joint destruction in rheumatoid arthritis. Ann Rheum Dis 2011; 70(9): 1562–8.
- 66. Klein-Wieringa IR, Van Der Linden MPM, Knevel R, Kwekkeboom JC, Van Beelen E, Huizinga TWJ et al. Baseline serum adipokine levels predict radiographic progression in early rheumatoid arthritis. Arthritis Rheum 2011; 63(9): 2567–74.
- 67. Meyer M, Sellam J, Fellahi S, Kotti S, Bastard JP, Meyer O et al. Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort. Arthritis Res Ther 2013; 15(6): 1–13.
- 68. Liu D, Luo S, Li Z. Multifaceted roles of adiponectin in rheumatoid arthritis. Int Immunopharmacol 2015; 28(2): 1084‐90.
- 69. Chennareddy S, Kishore Babu KV, Kommireddy S, Varaprasad R, Rajasekhar L. Serum adiponectin and its impact on disease activity and radiographic joint damage in early rheumatoid arthritis—A cross-sectional study. Indian J Rheumatol 2016; 11: 82–5. doi: 10.1016/j.injr.2016.01.006.
- 70. Senolt L, Pavelka K, Housa D, Haluz.k M. Increased adiponectin is negatively linked to the local inflammatory process in patients with rheumatoid arthritis. Cytokine 2006; 35(5-6): 247–52.
- 71. Khajoei S, Hassaninevisi M, Kianmehr N, Seif F, Khoshmirsafa M, Shekarabi M, Samei A, Haghighi A. Serum levels of adiponectin and vitamin D correlate with activity of rheumatoid arthritis. Mol Biol Rep 2019; 46: 2505–12.
- 72. Hoffman E, Rahat MA, Feld J, Elias M, Rosner I, Kaly L, Lavie I, Gazitt T, Zisman D. Effects of tocilizumab, ananti-interleukin-6 receptor antibody, on serum lipid and adipokine levels in patients with rheumatoid arthritis. Int J Mol Sci 2019; 20: 4633.
- 73. Qian J, Xu L, Sun X, Wang Y, Xuan W, Zhang Q et al. Adiponectin aggravates bone erosion by promoting osteopontin production in synovial tissue of rheumatoid arthritis. Arthritis Res Ther 2018; 20: 26. https://doi.org/10.1186/s13075-018-1526-y
- 74. DeClercq V, Cui Y, Forbes C, Grandy SA, Keats M, Parker L, Sweeney E, Yu ZM, Dummer TJB. Adiposity measures and plasma adipokines in females with rheumatoid and osteoarthritis. Mediat Inflamm 2017; 2017: 4302412.
- 75. Zhao YL, Zhang TP, Wu J, Li BZ, Li XM, Pan HF, Ye DQ. Association of adiponectin and adiponectin receptor gene polymorphisms with rheumatoid arthritis in a Chinese population. Postgrad Med J 2020; 96, 149–55.
- 76. Lee YH, Bae SC. Circulating adiponectin and visfatin levels in rheumatoid arthritis and their correlation with disease activity: a meta-analysis. Int J Rheum Dis 2018; 21: 664–72.
- 77. Ebina K, Fukuhara A, Ando W, Hirao M, Koga T, Oshima K et al. Serum adiponectin concentrations correlate with severity of rheumatoid arthritis evaluated by extent of joint destruction. Clin Rheumatol 2009; 28(4): 445–51.
- 78. Fatel EC, Rosa FT, Simão ANC, Dichi I. Adipokines in rheumatoid arthritis. Adv Rheumatol 2018; 58(1). doi:10.1186/s42358-018-0026-8
- 79. Kitahara K, Kusunoki N, Kakiuchi T, Suguro T, Kawai S. Adiponectin stimulates IL‐8 production by rheumatoid synovial fibroblasts. Biochem Biophys Res Commun 2009; 378(2): 218‐23.
- 80. Tang CH, Chiu YC, Tan TW, Yang RS, Fu WM. Adiponectin enhances IL‐6 production in human synovial fibroblast via an Adipo R1 receptor, AMPK, p38, and NFkappa B pathway. J Immunol 2007; 179(8): 5483‐92.
- 81. Choi HM, Lee YA, Lee SH, Hahm DH, Choi SY, Yang HI et al. Adiponectin may contribute to synovitis and joint destruction in rheumatoid arthritis by stimulating vascular endothelial growth factor, matrix metalloproteinase‐ 1, and matrix metalloproteinase‐13 expression in fibroblast‐like synoviocytes more than proin proinflammatory mediators. Arthritis Res Ther 2009; 11(6): R161. https://doi.org/10.1186/ar2844
- 82. Neumann E, Junker S, Schett G, Frommer K, Muller-Ladner U. Adipokines in bone disease. Nat Rev Rheumatol 2016; 12: 296–302.
- 83. Lei Y, Li X, Gao Z, Liu Y, Zhang B, Xia L et al. Association between adiponectin and clinical manifestations in rheumatoid arthritis. J Interferon Cytokine Res 2020; 40: 501–8.
- 84. Vasileiadis GK, Lundell AC, Zhang Y, et al. Adipocytokines in untreated newly diagnosed rheumatoid arthritis: association with circulating chemokines and markers of inflammation. Biomolecules 2021; 11(2): 325. Published 2021 Feb 21. doi:10.3390/biom11020325
- 85. Neumann E, Hasseli R, Ohl S, Lange U, Frommer KW, Müller-Ladner U. Adipokines and autoimmunity in inflammatory arthritis. Cells 2021; 10(2): 216. Published 2021 Jan 22. doi:10.3390/cells10020216